| Name | Title | Contact Details |
|---|
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE`s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate (SDC)- based antimicrobials, represent innovative advances in diverse markets and lead today`s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).
Protox Therapeutics Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations.
EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.